Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:50 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intranasal device Clear all
Completed Phase 3 Interventional

Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure

NCT00665977
View directory record Official record
Conditions
Obstructive Sleep Apnea, Nasal Congestion, Sinus Congestion
Interventions
Thermosmart & placebo, Placebo Device & Nasacort, Placebo Arm
Drug · Device
Lead sponsor
Clayton Sleep Insititute
Industry
Eligibility
16 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
View directory record Official record
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Nov 3, 2026, 1:50 PM EST
Completed Not applicable Interventional Results available

Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

NCT02313454
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 1 Interventional

CNS Uptake of Intranasal Glutathione

NCT02324426
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Revitalize Study in Older Adults at Risk for Alzheimer's Disease

NCT04018092
View directory record Official record
Conditions
Cognitive Aging, Alzheimer Disease, Protection Against
Interventions
Active NIR-PBM, Sham NIR-PBM
Device
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 89 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2 Interventional

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

NCT02424708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione 100mg, Reduced Glutathione 200mg, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Nov 3, 2026, 1:50 PM EST
Not listed Not applicable Interventional

Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

NCT03724136
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia, Mixed, Parkinson-Dementia Syndrome, Chronic Traumatic Encephalopathy, Huntington's Dementia, Wernicke Korsakoff Syndrome, Traumatic Brain Injury, Dementia, Multi-Infarct, Autism, Autism Spectrum Disorder, Autistic Behavior, Autistic Disorder, Current or Active State, Cadasil, LATE Limbic-predominant Age-related TDP-43 Encephalopathy
Interventions
Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Nov 3, 2026, 1:50 PM EST
Enrolling by invitation No phase listed Observational

Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years

NCT07521371
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Autism Spectrum Disorder High-Functioning, Autism Spectrum Disorder With Absence of Functional Language, Autism Spectrum Disorder With Impaired Functional Language, Autistic Disorder of Childhood Onset With Full Syndrome, Autistic Disorders Spectrum, Autistic Disorder, Autistic Disorder in Children and Adolescents, Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities
Interventions
Not listed
Lead sponsor
Healing Hope International
Other
Eligibility
4 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Spring, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2 Interventional Results available

Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.

NCT02437669
View directory record Official record
Conditions
Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Columbia University
Other
Eligibility
4 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2Phase 3 Interventional Results available

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

NCT01997411
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Nasal Glucagon, Intramuscular Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 3, 2026, 1:50 PM EST
Completed Not applicable Interventional Results available

Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease

NCT03405662
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Vielight Neuro Gamma, Sham Vielight Neuro Gamma
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Nov 3, 2026, 1:50 PM EST
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

NCT07703475
View directory record Official record
Conditions
COVID -19
Interventions
RVX-sCPD9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

NCT03942406
View directory record Official record
Conditions
Pertussis, Whooping Cough
Interventions
BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Combination Product
Lead sponsor
ILiAD Biotechnologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Cleveland, Ohio • Tomball, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Nov 3, 2026, 1:50 PM EST
Completed Not applicable Interventional Results available

Scalp Application of LED Therapy to Improve Thinking and Memory in Veterans With Gulf War Illness

NCT01782378
View directory record Official record
Conditions
Gulf War Veterans Illness, Neurobehavioral Manifestations, Memory Disorders
Interventions
Real LED Treatment, Sham LED Treatment
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
38 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 1Phase 2 Interventional Results available

Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children

NCT04586504
View directory record Official record
Conditions
Procedural Anxiety
Interventions
Intranasal midazolam
Drug
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 7 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 1Phase 2 Interventional Results available

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Nov 3, 2026, 1:50 PM EST
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 3, 2026, 1:50 PM EST
Not listed Phase 1Phase 2 Interventional

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

NCT04071600
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions
Neuropeptide Y, Placebo
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 3, 2026, 1:50 PM EST
Not yet recruiting Phase 1Phase 2 Interventional

Nebulized Nasal Steroids

NCT07270302
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
nebulized budesonide via NasoNeb, budesonide lavage via NeilMed
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Nov 3, 2026, 1:50 PM EST
Not yet recruiting Phase 1 Interventional

Topical TOR-582 Treatment of Epistaxis in HHT

NCT07667413
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Interventions
Topical sirolimus ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 3, 2026, 1:50 PM EST
Completed Phase 3 Interventional Results available

Intranasal Dexmedetomidine Premedication in Children

NCT02250703
View directory record Official record
Conditions
Preoperative Sedation
Interventions
Midazolam, Dexmedetomidine
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
5 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Nov 3, 2026, 1:50 PM EST
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.

NCT04810494
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
2% Lidocaine HCl topical solution, 0.9% Sodium chloride
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Nov 3, 2026, 1:50 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell

NCT01021176
View directory record Official record
Conditions
Food Intake
Interventions
Placebo spray, Diltiazem
Other · Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Nov 3, 2026, 1:50 PM EST